ArticlePloS one2020

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.

Tatiane Bomfim Ribeiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.